The current use of vasoactive agents in cardiogenic shock related to myocardial infarction and acute decompensated heart failure

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Ana Florencia Becerra , Udochukwu Amanamba , Jonathan E. Lopez , Noah J. Blaker , David E. Winchester
{"title":"The current use of vasoactive agents in cardiogenic shock related to myocardial infarction and acute decompensated heart failure","authors":"Ana Florencia Becerra ,&nbsp;Udochukwu Amanamba ,&nbsp;Jonathan E. Lopez ,&nbsp;Noah J. Blaker ,&nbsp;David E. Winchester","doi":"10.1016/j.ahjo.2025.100524","DOIUrl":null,"url":null,"abstract":"<div><div>Cardiogenic shock (CS) is a heterogeneous condition associated with exceptionally high mortality rates, despite significant advances in the field of cardiology. The primary causes of CS are myocardial infarction-related CS (AMI-CS) and acute decompensated heart failure-related CS (ADHF-CS). Management of CS is inherently complex, with the initial focus—irrespective of the underlying etiology—centered on preserving end-organ perfusion. Parenteral vasopressors and inotropes are the cornerstone of therapy to achieve this objective. However, data on the comparative efficacy of different vasoactive agents in CS remain limited, and no single agent has demonstrated clear superiority. Recent progress in the staging and phenotyping of CS has provided a framework for more tailored therapeutic approaches. This review offers a comprehensive and updated summary of current evidence on the use of vasopressors and inotropes in AMI-CS and ADHF-CS, including a discussion of specific scenarios, such as right ventricular CS (RV-CS).</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"52 ","pages":"Article 100524"},"PeriodicalIF":1.3000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal plus : cardiology research and practice","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666602225000278","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Cardiogenic shock (CS) is a heterogeneous condition associated with exceptionally high mortality rates, despite significant advances in the field of cardiology. The primary causes of CS are myocardial infarction-related CS (AMI-CS) and acute decompensated heart failure-related CS (ADHF-CS). Management of CS is inherently complex, with the initial focus—irrespective of the underlying etiology—centered on preserving end-organ perfusion. Parenteral vasopressors and inotropes are the cornerstone of therapy to achieve this objective. However, data on the comparative efficacy of different vasoactive agents in CS remain limited, and no single agent has demonstrated clear superiority. Recent progress in the staging and phenotyping of CS has provided a framework for more tailored therapeutic approaches. This review offers a comprehensive and updated summary of current evidence on the use of vasopressors and inotropes in AMI-CS and ADHF-CS, including a discussion of specific scenarios, such as right ventricular CS (RV-CS).
心源性休克(CS)是一种异质性疾病,尽管心脏病学领域取得了重大进展,但其死亡率却极高。导致心源性休克的主要原因是心肌梗死相关性休克(AMI-CS)和急性失代偿性心力衰竭相关性休克(ADHF-CS)。急性心肌梗死的治疗本身就很复杂,无论其病因如何,最初的治疗重点都是保护终末器官灌注。肠外血管加压药和肌注药是实现这一目标的治疗基石。然而,不同血管活性药物在 CS 中的疗效比较数据仍然有限,没有一种药物显示出明显的优越性。CS 分期和表型方面的最新进展为更有针对性的治疗方法提供了框架。本综述全面总结了目前在 AMI-CS 和 ADHF-CS 中使用血管加压药和肌力药的最新证据,包括对特定情况(如右心室 CS(RV-CS))的讨论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
0
审稿时长
59 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信